Complement C2 siRNA mediated therapy of myasthenia gravis in mice

Journal of Autoimmunity

Volumn 42, Issue , 2013, Pages 94-104

  Huda, Ruksana ^a   Tüzün, Erdem ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Autoimmunity; C2 siRNA; Classical pathway; Complement; Experimental autoimmune myasthenia gravis; Myasthenia gravis

Indexed keywords

CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M ANTIBODY; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FORELIMB; IMMUNIZATION; MOUSE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; TREATMENT DURATION;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C2; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIVER; MICE; MICE, INBRED C57BL; MUSCLES; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC; RNA, SMALL INTERFERING;

EID: 84877108697     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.01.003     Document Type: Article

References (30)

1. Vincent A., Drachman D.B. Myasthenia gravis. Adv Neurol 2002, 88:159-188.
2. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978, 298:1116-1122.
3. Sahashi K., Engel A.G., Lambert E.H., Howard F.M. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980, 39:160-172.
4. Lennon V.A., Seybold M.E., Lindstrom J.M., Cochrane C., Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978, 147:973-983.
5. Kaminski H.J., Li Z., Richmonds C., Lin F., Medof M.E. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 2004, 189:333-342.
6. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin Immunol 2000, 94:75-87.
7. Tuzun E., Christadoss P. Targeting classical complement pathway and IL-6 in experimental autoimmune myasthenia gravis. Myasthenia gravis: mechanisms of disease and immune intervention 2010, Linus Publication, Inc, New York. P. Christadoss (Ed.).
8. Tüzün E., Scott B.G., Goluszko E., Higgs S., Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 2003, 171:3847-3854.
9. Tüzün E., Li J., Saini S.S., Yang H., Christadoss P. Targeting classical complement pathway to treat complement mediated autoimmune diseases. Adv Exp Med Biol 2008, 632:265-272.
10. Tsujihata M., Yoshimura T., Satoh A., Kinoshita I., Matsuo H., Mori M., et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 1989, 39:1359-1363.
11. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J Immunol 1988, 140:2589-2592.
12. Nakano S., Engel A.G. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993, 43:1167-1172.
13. Tüzün E., Li J., Saini S.S., Yang H., Christadoss P. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 2007, 182:167-176.
14. Zheng X., Zhang X., Feng B., Sun H., Suzuki M., Ichim T., et al. Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol 2008, 173:973-980.
15. Zheng X., Feng B., Chen G., Zhang X., Li M., Sun H., et al. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 2006, 6:2099-2108.
16. Schultz D.R. Complement in host defense. Scand J Infect Dis Suppl 1980, (Suppl 24):22-29.
17. Karlsson E., Arnberg H., Eaker D. Isolation of the principal neurotoxin of two Naja naja subspecies. Eur J Biochem 1971, 21:1-16.
18. Wu B., Goluszko E., Huda R., Tüzün E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol 2011, [Chapter 15]:Unit 15.23.
19. Yang H., Tüzün E., Alagappan D., Yu X., Scott B.G., Ischenko A., et al. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol 2005, 175:2018-2025.
20. Falus A., Beuscher H.U., Auerbach H.S., Colten H.R. Constitutive and IL 1-regulated murine complement gene expression is strain and tissue specific. J Immunol 1987, 138:856-860.
21. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdörfer B., Giese T., et al. Quantitative expression of toll-like receptor 1 -10 mRNA and sensitivity to CpG oligodeoxynucleotides in cellular subsets of human peripheral blood mononuclear cells. J Immunol 2002, 168:4531-4537.
22. Nishimura M., Shinsaku N. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005, 28:886-892.
23. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301:640-643.
24. Uehara A., Fujimoto Y., Fukase K., Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflamatory cytokines. Mol Immunol 2007, 44:3100-3111.
25. Weber C., Müller C., Podszuweit A., Montino C., Vollmer J., Forsbach A. Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology 2012, 136:64-77.
26. Szebeni J. The complement system: novel roles in health and disease 2004, 201-229. Springer Verlag, Berlin, Heidelberg. J. Szebeni (Ed.).
27. Takata Y., Kinoshita T., Kozono H., Takeda J., Tanaka E., Hong K., et al. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway. J Exp Med 1987, 165:1494-1507.
28. Rawal N., Pangburn M.K. Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem 2003, 278:38476-38483.
29. Tüzün E., Huda R., Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun 2011, 37:136-143.
30. Inal J.M., Schneider B., Armanini M., Schifferli J.A. A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice. J Immunol 2003, 170:4310-4317.